Tenax Therapeutics presents full results from its Phase 3 LEVEL clinical trial for TNX-103 (oral levosimendan). The presentation occurs at the European Society of Cardiology (ESC) Congress, which began on August 28, 2026. The presentation features in a Late-Breaking Clinical Science session, a spot typically reserved for clinically significant data.
The company previously announced topline results on August 10, 2026. The trial did not meet its primary endpoint. This endpoint aimed to improve the 6-minute walk distance in patients with pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF). Despite the negative main outcome, the company reported positive signs in prespecified subgroup analyses. The full presentation details these findings.